• Regorafenib (BAY 73-4506): Advanced Assay Precision in Tumor

  2026-06-27

  Explore the advanced application of Regorafenib (BAY 73-4506) in precision cancer biology research. This article uncovers unique mechanistic insights and practical protocol strategies, establishing a new benchmark for angiogenesis and tumor progression studies.

• CHIR-99021: Precision GSK-3 Inhibition for Stem Cell Protoco

  2026-06-26

  CHIR-99021 (CT99021) delivers unmatched selectivity for GSK-3α/β, enabling robust control of stem cell pluripotency and differentiation. This article distills experimental workflows, troubleshooting, and recent cross-signaling insights to maximize the compound’s impact in advanced cell engineering.

• 10074-G5: Potent Small-Molecule c-Myc Inhibitor for Cancer R

  2026-06-26

  10074-G5 is a validated small-molecule c-Myc inhibitor that disrupts c-Myc/Max dimerization and demonstrates in vitro and in vivo efficacy in cancer models. With well-characterized IC50 values and robust effects on cell cycle arrest and apoptosis, it is a benchmark tool for dissecting oncogenic transcriptional networks in cancer research.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-06-25

  The 2026 study reveals that the fluoropyrimidine polymer CF10, when combined with 5-ethynyl-2′-deoxyuridine (EdU), promotes telomere attrition and mitotic catastrophe in colorectal cancer cells by enhancing EdU incorporation and DNA damage. These findings suggest a unique mechanism for leveraging DNA-directed therapies in telomerase-targeted oncology research.

• Genetic Engineering Boosts T Cell Immunity in Immune-Cold Tu

  2026-06-25

  He et al. introduce a tumor-specific genetic engineering strategy that synergistically enhances T cell infiltration and activity in immune-cold solid tumors. By leveraging a dual-function plasmid vector, the study demonstrates improved efficacy of checkpoint inhibitors and CAR-T therapies with minimal systemic toxicity, offering a promising approach for overcoming resistance in solid tumor immunotherapy.

• Selective Autophagy Regulates IRF3 Stability in Antiviral Im

  2026-06-24

  Wu et al. (2021) uncover how selective autophagy, mediated by CALCOCO2/NDP52 and regulated by PSMD14/POH1, precisely controls IRF3 degradation, balancing type I interferon production and immune suppression. These insights deepen our understanding of innate immune signaling modulation and present new approaches for studying transcription factor regulation in antiviral contexts.

• Enhancing Mammalian Cell Viability Assays with Live-Dead Cel

  2026-06-23

  This article explores how the Live-Dead Cell Staining Kit I (Calcein AM/PI), SKU K2247, addresses core challenges in mammalian cell viability and cytotoxicity assays. Drawing on validated protocols and scenario-driven questions, we demonstrate how this kit delivers reproducible, sensitive results for biomedical researchers, supporting robust data interpretation and workflow reliability.

• AZD6482: Distinct Mechanistic Insights into PI3Kβ Inhibition

  2026-06-23

  Explore how the PI3Kβ inhibitor AZD6482 enables refined experimental design and nuanced pathway exploration. This guide provides advanced, evidence-based perspectives distinct from protocol-centric articles.

• Vorinostat: Epigenetic Modulation and Apoptosis Applications

  2026-06-22

  Vorinostat (suberoylanilide hydroxamic acid) is revolutionizing epigenetic modulation and apoptosis studies in cancer biology by providing precise, reproducible workflows. This article unpacks cutting-edge protocols, troubleshooting strategies, and novel insights from recent RNA Pol II research, empowering researchers to maximize experimental impact.

• miR-196a Drives Esophageal Adenocarcinoma via c-Myc/TERT/NFκ

  2026-06-22

  This study uncovers how microRNA-196a (miR-196a) promotes aggressiveness in esophageal adenocarcinoma by engaging the c-Myc/TERT/NFκB axis. These mechanistic insights highlight new molecular targets for cancer research and underscore the value of c-Myc inhibition in exploring EAC progression.

• APEX2 Drives TERT Expression in Human Embryonic Stem Cells

  2026-06-21

  This study uncovers a novel requirement for the DNA repair enzyme APEX2 in the efficient expression of TERT, the catalytic subunit of telomerase, in human embryonic stem cells. The findings reshape our understanding of telomerase regulation and introduce repetitive DNA element repair as a key control point, with implications for aging and cancer research.

• X-Gal in Sensory Biology: Precision Tools for OSN Assays

  2026-06-20

  Explore how X-Gal, a premier chromogenic substrate, enables advanced blue-white screening and molecular assays in olfactory sensory neuron (OSN) research. This article reveals unique mechanistic insights and practical protocols for leveraging X-Gal in the study of sensory adaptation and gene regulation.

• Panobinostat (LBH589): Advanced HDAC Inhibitor Workflows

  2026-06-19

  Panobinostat (LBH589) from APExBIO empowers researchers to interrogate apoptosis and epigenetic regulation in cancer models with nanomolar precision. Discover optimized protocols, troubleshooting strategies, and novel mechanistic insights that set this HDAC inhibitor apart for translational and resistance research.

• miR-24-3p–Sp1/PI3K Axis in Doxorubicin-Induced Cardiac Injur

  2026-06-19

  This study uncovers a regulatory axis in doxorubicin-induced heart failure, demonstrating that miR-24-3p exacerbates cardiac dysfunction by suppressing Sp1/PI3K signaling. Silencing miR-24-3p confers protection against apoptosis and oxidative stress, presenting new mechanistic insight and therapeutic potential for cardiac injury models.

• (S)-(+)-Ibuprofen: Advancing Precision in Inflammation Resea

  2026-06-18

  This article offers translational researchers a mechanistic, strategic, and environmental perspective on (S)-(+)-Ibuprofen, highlighting its unique value as a reference COX inhibitor for inflammation pathway and pain mechanism research. By integrating biologically grounded rationale, practical protocol guidance, and emerging concerns about environmental persistence, we provide a forward-looking framework that extends beyond standard product pages. The discussion bridges experimental, clinical, and ecological domains—empowering researchers to make informed, responsible choices with APExBIO’s (S)-(+)-Ibuprofen.

3776 records 14/252 page Previous Next First page 上5页 1112131415 下5页 Last page